Category: Comparisons

BPC-157 and TB-500 are the two names that come up most in conversations about “healing peptides,” often together as the so-called Wolverine stack. The hype online runs far ahead of the science. This guide compares them side by side and is honest about what is known, what is guessed, and what nobody has tested yet.

BPC-157 vs TB-500 at a glance

	BPC-157	TB-500
Full name	Body Protection Compound-157	Synthetic thymosin beta-4 fragment/analog
Size	15 amino acids	Varies by seller; based on the active region of a 43-amino-acid protein
Origin	Derived from a protein in human gastric juice	Based on thymosin beta-4, found in nearly all human cells
Main research areas	Gut lining, tendon, ligament, muscle and blood vessel repair	Cell migration, wound healing, heart and eye tissue repair
Human evidence	A few very small pilot reports, no large controlled trials	None for TB-500 itself; the parent protein has had some human trials
FDA status	Not approved	Not approved
WADA status	Prohibited (S0, named specifically)	Prohibited (S2, thymosin beta-4 and derivatives)

What is BPC-157?

BPC-157 was developed and studied mainly by a research group at the University of Zagreb in Croatia. It’s a synthetic sequence taken from a larger protein found in gastric juice. One reason it gets attention is that it appears unusually stable in stomach acid for a peptide, which is why both oral and injected forms have been studied in animals.

Proposed mechanisms

Animal and cell studies suggest BPC-157 may:

• Encourage angiogenesis (new blood vessel growth), which helps bring nutrients to healing tissue
• Interact with the nitric oxide system, which affects blood flow
• Influence growth-factor signaling involved in tendon and ligament repair
• Protect the lining of the stomach and intestines in rodent injury models

What the research shows

Hundreds of rodent studies report faster healing of tendons, ligaments, muscle, bone and gut injuries. That sounds impressive, but there are big caveats: much of the work comes from one research group, the doses are given per kilogram of rat, and rodent healing results frequently don’t carry over to people. Human data is limited to a couple of very small pilot reports without control groups.

What is TB-500?

Thymosin beta-4 (Tβ4) is a natural 43-amino-acid protein that binds actin, a structural protein cells use to move and change shape. Because repair cells need to migrate into damaged tissue, Tβ4 became a research target for wound healing.

“TB-500” is a name used in the research market for synthetic peptides based on the active region of Tβ4. What’s actually in a TB-500 vial can differ from seller to seller, which is one more reason to check a certificate of analysis.

What the research shows

Animal studies of Tβ4 report benefits in skin wounds, heart tissue after injury, and the cornea. The full-length protein has been tested in human clinical trials as an eye drop for dry eye and corneal conditions, with mixed results. None of that is the same as injecting a research-market TB-500 product, and no human dose for TB-500 exists.

Why people combine them

The theory behind the combination is that they act on different parts of the healing process: BPC-157 on blood supply and growth-factor signaling, TB-500 on cell movement. That’s a reasonable hypothesis, but it is only a hypothesis. We found no controlled studies testing the two together, in animals or people.

Safety: what we don’t know

• No long-term human safety data exists for either compound.
• Growth signals cut both ways. Anything that promotes blood vessel growth and cell migration raises theoretical questions about existing tumors. This hasn’t been proven, but it hasn’t been ruled out either.
• Product quality varies. Research-market products aren’t made under drug manufacturing rules. Contamination, wrong compounds and wrong amounts are real risks.
• Regulatory status. The FDA has flagged BPC-157 as a bulk substance with potential safety risks for compounding. Check the FDA’s current lists, as this area changes.

Dosing

Following Pep Guide’s policy: there is no established human dose for BPC-157 or TB-500, because neither has an FDA label or adequate human trials. Numbers you see online are extrapolated from animal studies or passed around in forums.

The bottom line

BPC-157 and TB-500 are interesting research compounds with a large body of animal work and almost no human evidence. They are not approved, not proven in people, and banned in tested sports. If you’re dealing with an injury, a sports medicine doctor or physical therapist has treatments with real human data behind them.

Related reading: Peptides and sports drug testing · How to spot a sketchy peptide vendor · Compound Library

“CJC-1295” is one of the most confusing names in the peptide world because it’s used for two different compounds. One lasts about a week in the body. The other lasts about half an hour. Mixing them up leads to a lot of bad information. Here’s how to tell them apart.

Background: what is GHRH?

Growth hormone–releasing hormone is made by the hypothalamus in the brain. It signals the pituitary gland to release growth hormone (GH) in pulses, mostly during deep sleep. GH then prompts the liver to make IGF-1, which drives many of GH’s effects on tissue.

Only the first 29 amino acids of GHRH are needed for activity. That fragment, GRF (1-29), is the starting point for both versions of CJC-1295. It’s also essentially what sermorelin is. See our GH secretagogues guide for the full family.

What “DAC” means

DAC stands for Drug Affinity Complex. It’s a chemical attachment that lets the peptide bond to albumin, the most common protein in blood. Albumin circulates for weeks, so a peptide riding on it avoids being quickly broken down or filtered out.

Both versions also include four amino acid substitutions that make the peptide more resistant to DPP-4, the enzyme that rapidly breaks down natural GHRH.

Side-by-side comparison

	CJC-1295 with DAC	CJC-1295 without DAC (Mod GRF 1-29)
Structure	Modified GRF (1-29) + DAC linker	Modified GRF (1-29) only
Half-life	~6–8 days in early human studies	~30 minutes
GH pattern	Sustained elevation over days	Short pulse, closer to natural release
Human research	Small early-phase studies in healthy adults (mid-2000s)	Very limited
Development	Clinical development discontinued	Never developed as an approved drug
FDA status	Not approved	Not approved
WADA status	Prohibited (S2)	Prohibited (S2)

What the human studies found (with DAC)

Early studies in healthy adults, published in 2006, found that a single injection of CJC-1295 with DAC raised GH levels several-fold for six days or more and raised IGF-1 for over a week. Pulsatile GH release appeared to be preserved, with a higher baseline. These were small, short studies designed to test safety and drug behavior, not long-term benefit. Clinical development was later stopped.

Why the difference matters

• Research design: a compound that lasts a week and one that lasts half an hour can’t be studied the same way. Timing, frequency and measured outcomes all differ.
• Physiology: the body naturally releases GH in pulses. A sustained elevation (with DAC) is a different signal from a short pulse (without DAC), and the long-term effects of either haven’t been established.
• Labeling confusion: products sold simply as “CJC-1295” may be either one. Check the full name and the mass spec result on the COA, since the two have very different molecular weights.

Why it’s often paired with ipamorelin

GHRH analogs and ghrelin mimetics like ipamorelin act on different receptors. In physiology research, combining the two pathways produces a larger GH response than either alone. That’s the rationale behind the popular CJC-1295/ipamorelin pairing. It’s a reasonable pharmacology idea, but there are no controlled long-term trials of the combination.

Safety considerations

• Early studies reported injection-site reactions, flushing, headache and temporary water retention.
• Raising GH and IGF-1 can reduce insulin sensitivity and affect blood sugar.
• Long-term effects of sustained GH/IGF-1 elevation, including effects on existing tumors, are unknown for these compounds.

Dosing

Following Pep Guide’s policy, we don’t list doses for CJC-1295 in either form. Neither version has an FDA label or adequate human trials establishing a dose.

Related: Stacks & Tracking · Compound Library